Patients with the brain cancer glioblastoma have about a year to live once diagnosed. Glioblastoma kills quickly as it grows aggressively and patients develop resistance to the anti-cancer drug temozolomide. Studies by a team at Virginia Tech indicate that a protein called Cx43 may hold the key to temozolomide resistance. Our researchers have found that a drug targeting Cx43 dramatically enhances the sensitivity of glioblastoma cancer cells to temozolomide, thereby providing the prospect of a novel combninatorial therapy for this deadly disease.